ABPI response to New Treatment Fund extension

The Welsh Minister for Health and Social Services, Vaughan Gething has today confirmed £16m to extend the New Treatment Fund, a scheme to speed up access to new medicines in Wales

The New Treatment Fund has an excellent track record in speeding up people’s access to new, clinically and cost-effective medicines.  We’re delighted to see that it will continue into 2022.  Ahead of the upcoming Senedd Elections, we’re looking for all political parties to pledge their support for the Fund and to ensure it features in the programme of the next Welsh Government. ABPI Cymru Wales Director Dr Rick Greville

The New Treatment Fund has enabled quicker access to over 265 medicines to treat more than 100 health conditions since it was established by the Welsh Government in 2017. It has cut the average time it takes for newly-recommended medicines to become available to patients by 85 per cent, from 90 to 13 days.

In response, ABPI Cymru Wales Director Rick Greville commented: 

“The New Treatment Fund has an excellent track record in speeding up people’s access to new, clinically and cost-effective medicines. We’re delighted to see that it will continue into 2022.

“Ahead of the upcoming Senedd Elections, we’re looking for all political parties to pledge their support for the Fund and to ensure it features in the programme of the next Welsh Government.

“Ensuring access to appropriate treatments at the right time will benefit patients, the NHS and the pharmaceutical industry across Wales.”

TAGS
  • New Treatment Fund

Last modified: 20 September 2023

Last reviewed: 20 September 2023

Related news

The ABPI exists to make the UK the best place in the world to research, develop and use new medicines. We represent companies of all sizes who invest in discovering the medicines of the future. 

Our members supply cutting edge treatments that improve and save the lives of millions of people. We work in partnership with Government and the NHS so patients can get new treatments faster and the NHS can plan how much it spends on medicines. Every day, we partner with organisations in the life sciences community and beyond to transform lives across the UK.